Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Public health experts, including the Centers for Disease Control and Prevention (CDC), recommend seasonal influenza vaccination as the first line of defense this year in protecting against the influenza virus.
PeriGen, Inc., today announced the release of its Influenza Prevention and Treatment Bundle to its North American client hospitals. In advance of the approaching flu season, PeriGen’s protocol bundle will help clinicians follow recommended guidelines for screening, preventing and treating as well as accurately reporting cases of seasonal flu and H1N1 (“Swine Flu”) to state and local officials.
MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million.
According to a recent IOM report, only 6 percent of U.S. hospital emergency departments are fully equipped to properly care for children. With high rates of novel H1N1 (swine) flu expected this winter, the time to address these deficiencies is immediate.
Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Building upon four decades of research and real world operation of electronic medical records and health information exchange, Regenstrief Institute researchers have developed, tested and are now operating innovative technologies to allow for the bi-directional flow of evidence-based medical information between clinical sources and public health organizations.
LSA (Language Services Associates), a leading provider of premium language-based solutions, today announced its comprehensive business continuity plan (BCP) for the 2009-2010 flu season. The strategy, which was devised by LSA’s BCP project management team, has been created to ensure the company is prepared for an increase in demand for language assistance in the event of a potential Swine Flu pandemic.
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.
The Defense Advanced Research Projects Agency (DARPA), the research arm of the U.S. Department of Defense, has awarded Duke University $19.5 million for an effort led by the Duke Institute for Genome Sciences & Policy (IGSP) to design a portable, easy-to-use diagnostic device that can reveal who is infected with an upper respiratory virus before the first cough or sneeze.
VeriChip Corporation (“VeriChip”) (NASDAQ: CHIP) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip has been granted an exclusive license to RECEPTORS' Patent No. 7,504,364 titled “Methods of Making Arrays and Artificial Receptors” and Patent No. 7,469,076 “Sensors Employing Combinatorial Artificial Receptors,” in their application to the development of the virus triage detection system for the H1N1 virus.
NPR reports: "In the Hispanic community, there are issues in the debate over health care that spill over into the debate over immigration policy."
The U.N. this week will request that wealthy nations and development banks donate $1.48 billion to help developing countries fight H1N1 (swine flu), Bloomberg reports. "Most of the money is needed for vaccines and drugs … to help the least-developed nations cope with the influenza pandemic, according to a U.N. report obtained" Monday by the news service.
The Centers for Disease Control and Prevention on Friday announced it anticipates 3.4 million doses of inhalable H1N1 vaccines will be available by the first week of October - the initial influx of 195 million doses purchased by the U.S. government, CNN reports. The vaccine is approved for healthy people between the ages of two and 49, but not for pregnant women (9/18).
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a “Master Service Agreement” with the Southern Research Institute (“Southern Research”), Birmingham, AL. Southern Research is a well established, prestigious institution that has performed preclinical testing services for several vaccines and antivirals.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA).
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been awarded a $77.2 million contract modification by the U.S. Department of Health & Human Services (HHS) to complete Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, for the treatment of complicated influenza.
TeleVox Software, Inc., a leading provider of communication solutions for the healthcare industry, today launched its Flu Preparedness Program (www.televox.com/fluprogram), designed to enable health care providers to give their patients the latest information about fighting the Flu and the H1N1 virus, commonly referred to as the swine flu. Doctors can easily communicate with their patients through a variety of methods such as voice, email, postcards and text messages.
Most workers have not had any direction from their employers about the upcoming flu season, according to a national survey released today by Mansfield Communications Inc.
Elsevier, a leading publisher of scientific, technical and medical information products and services, announced today, that its journal Vaccine, the most comprehensive and pre-eminent journal for those interested in vaccines and vaccination, will organize the 3rd Vaccine Global Congress from 4-6 October, 2009, in Singapore.
In addition to the Lancet's recent publication of an opinion piece and letter by 18 doctor association leaders about the potential health risks associated with climate change, the journal includes an editorial about sexual and reproductive health and climate change and a comment on the upcoming Copenhagen conference in December (9/19).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.